Myelo Therapeutics Receives Additional NIAID Funding to Advance Development of Myelo001 for Acute Radiation Syndrome
Myelo Therapeutics GmbH, a clinical-stage pharmaceutical company focused on developing medical countermeasures (MCM) and therapies for cancer supportive care, announced today that the U.S. National Institute of Allergy and Infectious Diseases…